Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Accounts Payables: 2019-2024

Historic Accounts Payables for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to $66.6 million.

  • Pharming Group N.V's Accounts Payables rose 7.69% to $78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.2 million, marking a year-over-year increase of 7.69%. This contributed to the annual value of $66.6 million for FY2024, which is 8.16% down from last year.
  • Pharming Group N.V's Accounts Payables amounted to $66.6 million in FY2024, which was down 8.16% from $72.5 million recorded in FY2023.
  • Pharming Group N.V's Accounts Payables' 5-year high stood at $72.5 million during FY2023, with a 5-year trough of $42.5 million in FY2021.
  • For the 3-year period, Pharming Group N.V's Accounts Payables averaged around $64.5 million, with its median value being $66.6 million (2024).
  • Its Accounts Payables has fluctuated over the past 5 years, first dropped by 10.89% in 2021, then skyrocketed by 33.16% in 2023.
  • Over the past 5 years, Pharming Group N.V's Accounts Payables (Yearly) stood at $47.7 million in 2020, then declined by 10.89% to $42.5 million in 2021, then rose by 28.23% to $54.5 million in 2022, then skyrocketed by 33.16% to $72.5 million in 2023, then fell by 8.16% to $66.6 million in 2024.